Overview
- The engineered adenovirus, called AR2015, uses a hybrid promoter built from A33 and vWA2 gene fragments identified through bioinformatic and AI analysis to confine replication to malignant cells and address tumor heterogeneity.
- In animal models bearing human colorectal liver metastases, intravenous dosing led to selective destruction of cancer cells without evident damage to healthy tissue, with responses reported to persist for up to a year.
- Tests on patient-derived tumor samples showed activity across all specimens evaluated, with at least one of the promoter targets expressed in each primary tumor and metastasis analyzed.
- Combining AR2015 with low doses of chemotherapy enhanced anti-tumor effects, with reports of complete eradication in some preclinical cases.
- Findings were published in Molecular Therapy: Oncology, and the team filed an international patent as they assemble the formal preclinical package required to launch clinical testing.